MiNK Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. (ticker INKT) is a U.S.-listed biotechnology company trading on the NASDAQ market in the United States, with principal executive offices in New York City. For investors, MiNK is a clinical-stage biotech focused on next-generation cell therapy, offering a high-risk, high-upside profile typical of early pipeline companies. The company was originally incorporated in 2017 as AgenTus Biosciences and later changed its name to MiNK Therapeutics in June 2021. It has strong historical ties to Agenus and has built its strategy around a proprietary allogeneic invariant natural killer T-cell (iNKT) platform designed for off-the-shelf use, avoiding the patient-specific manufacturing burden associated with many autologous cell therapies. MiNK’s core business is the discovery, development, manufacturing, and potential commercialization of iNKT-based therapies aimed at modulating immune function in oncology and immune-mediated diseases. Its lead asset, agenT-797, is a cryopreserved allogeneic iNKT cell therapy being studied across multiple settings, including solid tumors, graft-versus-host disease (GvHD), and severe inflammatory lung disease such as acute respiratory distress syndrome (ARDS). The company has also described a pipeline of next-generation engineered iNKT programs, including CAR-iNKT approaches and antigen-targeted constructs, alongside external collaborations intended to broaden the platform into pediatric cancers and additional unmet-need indications. From a competitive standpoint, MiNK seeks differentiation through three main attributes: an allogeneic, scalable platform; a broader immune-restoration thesis beyond oncology alone; and in-house manufacturing capabilities intended to improve reproducibility and support clinical execution. This positions the company differently from more conventional CAR-T developers, which often rely on individualized workflows that can be more complex and expensive. However, MiNK remains early-stage, meaning its investment case depends heavily on clinical validation, partner funding, and careful capital allocation. During 2025 and into 2026, MiNK reported a steady flow of clinical and strategic updates, including Phase 2 progress for agenT-797 in checkpoint-refractory gastroesophageal cancer, publications and conference presentations in ARDS, expansion work in idiopathic pulmonary fibrosis (IPF), and a collaboration with C-Further to advance a PRAME-targeted iNKT program in pediatric oncology. These developments reinforce the company’s catalyst-driven profile, but also underscore that it remains a speculative NASDAQ biotech whose valuation will be shaped primarily by clinical readouts and execution rather than near-term commercial revenue.